Revolution Medicines, Inc.

Revolution Medicines, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on precision oncology. It develops small-molecule therapies designed to target RAS-addicted cancers, with its pipeline centered on RAS(ON) inhibitors and related combination approaches.

7.14

— Revolution Medicines, Inc.
	%
RAS(ON) Inhibitors	0% Small-molecule therapies designed to inhibit the active, GTP-bound form of RAS in cancer cells.
Precision Oncology Pipeline	0% Clinical and preclinical oncology programs built around genetic drivers and resistance biology.
Combination Therapy Development	0% Programs that test RAS-targeted agents with other therapies to improve response and durability.
Collaboration Revenue	100% Research collaboration arrangements that support discovery and biomarker work.

The company’s direct counterparties are primarily pharmaceutical collaborators, research partners, and contract...

Research collaboratorssecondary
Pharmaceutical and biotech partners that support discovery, preclinical work, or biomarker programs.
Clinical trial sites and investigatorsprimary
Cancer centers and physicians that enroll patients and generate clinical data for pipeline advancement.
Future oncology prescribersprimary
Oncologists who would prescribe approved RAS-targeted therapies in relevant cancer indications.
Third-party payorsprimary
Commercial insurers and government programs that determine coverage, pricing, and reimbursement.

Revolution Medicines is headquartered in the United States and expects its first commercial launch, if approved, to be...

•Headquartered in the United States
•First expected commercial launch would be in the U.S.
•Europe and Asia are planned follow-on markets
•International reimbursement rules can affect pricing and access
•Manufacturing is outsourced to third-party CDMOs

The company is building a portfolio of RAS(ON) inhibitors for RAS-addicted cancers and intends to retain meaningful...

Advance lead RAS(ON) inhibitor programsshort-term

Clinical proof of concept is central to validating the platform and creating future product value.

Build combination and biomarker capabilitiesmedium-term

Combination regimens and biomarker insights can improve response rates and patient selection.

Prepare for commercialization in major marketsmedium-term

A direct launch model requires medical, regulatory, manufacturing, and market access readiness.

The business depends on successful clinical development of unproven RAS-targeted therapies, and failure in preclinical...

critical

Clinical development failure

Pipeline value depends on demonstrating safety and efficacy in human trials.

Scope: Lead RAS(ON) inhibitor programs
Materiality: high

high

Scientific uncertainty around direct RAS inhibition

The target has historically been difficult to drug, so the mechanism may not translate into durable approvals.

Scope: RAS(ON) platform
Materiality: high

high

Financing risk

The company will need substantial capital before product sales can fund operations.

Scope: Development and commercialization build-out
Materiality: high

medium

Reimbursement and pricing pressure

Oncology drugs depend on coverage decisions and may face price controls or negotiation.

Scope: U.S., Europe, and Asia commercialization
Materiality: medium

medium

Manufacturing and supply dependence

All manufacturing is outsourced to CDMOs, creating third-party execution and quality risk.

Scope: Clinical and future commercial supply
Materiality: medium

Research and development expense accruals

Can shift quarterly operating loss materially

Collaboration revenue recognition

Affects timing and amount of non-product revenue

Liability related to sale of future royalties

Can create significant non-cash balance-sheet and P&L volatility

Prepaid R&D and deferred advance payments

Affects expense timing across reporting periods

Revolution Medicines, Inc.

Clinical development failure

Scientific uncertainty around direct RAS inhibition

Financing risk

Reimbursement and pricing pressure

Manufacturing and supply dependence

Innoviva, Inc.

Rezolute, Inc.

RHYTHM PHARMACEUTICALS, INC.

Modular Medical, Inc.

Disc Medicine, Inc.

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.